Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trimegestone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 8/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 11/20 | 0.58 |
| ▸ | AR | P10275 | 5/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimegestone SCHEMBL13752884 | 1.00 | PGR (0.72) | PGRNR3C1ARNR3C2CYP3A4 | |
| Trimegestone SCHEMBL6847373 | 1.00 | PGR (0.72) | PGRNR3C1ARNR3C2CYP3A4 | |
| Trimegestone SCHEMBL3691258 | 1.00 | PGR (0.72) | PGRNR3C1ARNR3C2CYP3A4 | |
| Trimegestone SCHEMBL17906556 | 1.00 | PGR (0.72) | PGRNR3C1ARNR3C2CYP3A4 | |
| Trimegestone SCHEMBL3155792 | 1.00 | PGR (0.72) | PGRNR3C1ARNR3C2CYP3A4 | |
| Trimegestone SCHEMBL13875056 | 1.00 | PGR (0.72) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL19286040 | 0.93 | PGR (0.74) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL13875044 | 0.90 | PGR (0.70) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL21231223 | 0.90 | PGR (0.70) | PGRNR3C1ARNR3C2CYP3A4 | |
| SCHEMBL20952986 | 0.89 | PGR (0.68) | PGRNR3C1ARNR3C2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | claimed |
| US-20260090995-A1 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | ESTETRA SRL (BE) | 2026-04-02 | — | — | US | claimed |
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| EP-4637777-A1 | USE OF ESTETROL IN HEPATICALLY IMPAIRED PATIENTS | Estetra SRL (BE) | 2025-10-29 | — | — | EP | claimed |
| US-12427114-B2 | Orodispersible dosage unit containing an estetrol component | ESTETRA SRL (BE) | 2025-09-30 | — | — | US | claimed |
| US-20250255968-A1 | INTRAVAGINAL DEVICES FOR DRUG DELIVERY | KISER PATRICK F (US) | 2025-08-14 | — | — | US | claimed |
| EP-4578442-A1 | MICROSPHERE COMPOSITION FOR CONTRACEPTIVE MICRONEEDLES AND CONTRACEPTIVE MICRONEEDLES COMPRISING THE SAME | Small'Lab Co., Ltd. (KR) | 2025-07-02 | — | — | EP | claimed |
| US-20250205250-A1 | MICROSPHERE COMPOSITION FOR CONTRACEPTIVE MICRONEEDLES AND CONTRACEPTIVE MICRONEEDLES COMPRISING THE SAME | SMALL'LAB CO., LTD. (KR) | 2025-06-26 | — | — | US | claimed |
| US-12318395-B2 | Ethinyl estradiol-β-cyclodextrin complex and process for preparing thereof | LABORATORIOS LEON FARMA, S.A. (ES) | 2025-06-03 | — | — | US | claimed |
| EP-4126235-A2 | IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | Vanda Pharmaceuticals Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4125828-A1 | ANTI-ANDROGEN OR AN ANDROGEN RECEPTOR ANTAGONIST FOR TREATMENT OF A VIRAL RESPIRATORY INFECTION | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2023-02-08 | — | — | EP | claimed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | claimed |
| CN-115335122-A | Identification of compounds and their use in the treatment and prevention of severe acute respiratory syndrome coronavirus 2 | 万带兰制药公司 | 2022-11-11 | — | — | CN | claimed |
| EP-4065224-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-10-05 | — | — | EP | claimed |
| US-20220186227-A1 | Therapeutic Targets for Oncogenic KRAS-Dependent Cancers | UNIVERSITY OF MASSACHUSETTS | 2022-06-16 | — | — | US | claimed |
| US-20220096385-A1 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | ESTETRA SPRL (BE) | 2022-03-31 | — | — | US | claimed |
| US-20220047629-A1 | Halogenated Fullerene Functionalized as a Biocidal and Chemotactic Spermicide to Vaginally Harbor and Neutralize Spermatozoa for Use as a Safe and Effective Contraceptive | BRADY TERRY EARL (AI) | 2022-02-17 | — | — | US | claimed |
| EP-3946629-A1 | THERAPEUTIC TARGETS FOR ONCOGENIC KRAS-DEPENDENT CANCERS | University Of Massachusetts (US) | 2022-02-09 | — | — | EP | claimed |
| EP-3943079-A1 | THERAPEUTIC AND METHOD OF USE | Predictive Therapeutics, LLC (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | PGRMC2, PGRMC1, PGR | PGR 3/4885NR3C1 1252/4885AR 74/4885 |
| US-20260090995-A1 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT | HSD17B11, CYP17A1, SRD5A2 | PGR 21/4885NR3C1 51/4885AR 335/4885 |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | NRP1, PGR, TNFRSF1A | PGR 2/4885NR3C1 36/4885AR 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.